← Back to Clinical Trials
Recruiting NCT07376655

NCT07376655 Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07376655
Status Recruiting
Phase
Sponsor Yale University
Condition Diabetes Type 2
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2026-06-04
Primary Completion 2027-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
App

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2026-06-04 with a primary completion date of 2027-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goals of this randomized trial is to learn: 1. If the Thrive AI Health app will help adults improve their everyday habits (diet, exercise, and sleep). 2. How often participants will use the Thrive AI Health app to which they will have free access The Thrive AI Health app uses artificial intelligence (AI) to give personalized advice. It is designed to help people eat better, exercise more, manage stress, and sleep well. Researchers will compare changes in diet, exercise and sleep in participants using the app to those participants not using the app. Participants will complete study questionnaires and an in-person visit at the beginning and end of the study.

Eligibility Criteria

Inclusion Criteria: * Be at high risk for chronic disease defined as: Body mass index (BMI)\>25 BMI\<=25 who are prediabetic or have type 2 diabetes * Aged 40 years or older Exclusion Criteria: * Unable to walk

Contact & Investigator

Central Contact

Melinda Irwin

✉ melinda.irwin@yale.edu

📞 203-785-6392

Principal Investigator

Melinda Irwin

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT07376655 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying Diabetes Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07376655 currently recruiting?

Yes, NCT07376655 is actively recruiting participants. Contact the research team at melinda.irwin@yale.edu for enrollment information.

Where is the NCT07376655 trial being conducted?

This trial is being conducted at New Haven, United States.

Who is sponsoring the NCT07376655 clinical trial?

NCT07376655 is sponsored by Yale University. The principal investigator is Melinda Irwin at Yale University. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology